PMCB (PharmaCyte Biotech) Days Payable: 0.00 (As of Jan. 2026)

What is PharmaCyte Biotech Days Payable?

PharmaCyte Biotech PMCB +1.44% 32 Days Payable is 0.00 as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, PharmaCyte Biotech ranks worse than 141442.57% on this metric.

PharmaCyte Biotech's average Accounts Payable for the three months ended in Jan. 2026 was $1.11 Mil. PharmaCyte Biotech's Cost of Goods Sold for the three months ended in Jan. 2026 was $0.00 Mil.

The historical rank and industry rank for PharmaCyte Biotech's Days Payable or its related term are showing as below:

PMCB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

PharmaCyte Biotech's Days Payable stayed the same from Jan. 2025 (0.00) to Jan. 2026 (0.00). stayed the same

PharmaCyte Biotech Days Payable Related Terms

PharmaCyte Biotech Days Payable Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Days Payable Chart

PharmaCyte Biotech Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

Days Payable

Get a 7-Day Free Trial

0.00

PharmaCyte Biotech Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

PMCB vs IMNN, ACXP, ENVB: Days Payable Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Days Payable distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Days Payable falls into.

Save Embed

32GF Score

PharmaCyte Biotech Inc PMCB

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmaCyte Biotech Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

PharmaCyte Biotech's Days Payable for the fiscal year that ended in Apr. 2025 is calculated as

	Days Payable (A: Apr. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Apr. 2024 )	+	Accounts Payable (A: Apr. 2025 ))	/	count )	/	Cost of Goods Sold (A: Apr. 2025 )	*	Days in Period
=	( (0.389	+	0.399)	/	2 )	/	0	*	365
=	0.394					/	0	*	365
=	N/A

PharmaCyte Biotech's Days Payable for the quarter that ended in Jan. 2026 is calculated as:

	Days Payable (Q: Jan. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Oct. 2025 )	+	Accounts Payable (Q: Jan. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Jan. 2026 )	*	Days in Period
=	( (1.021	+	1.2)	/	2 )	/	0	*	365 / 4
=	1.1105					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

PharmaCyte Biotech (PMCB) has a Days Payable of 0.00 as of Jan. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #999999 out of 707 companies in the Biotechnology industry.

Is PharmaCyte Biotech's Days Payable too high?

PharmaCyte Biotech's current Days Payable is 0.00. Based on the distribution chart, PharmaCyte Biotech ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does PharmaCyte Biotech's Days Payable compare to IMNN and ACXP?

According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #999999 out of 707 companies for Days Payable. This places PharmaCyte Biotech in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmaCyte Biotech stock overvalued right now?

PharmaCyte Biotech (PMCB) has a current Days Payable of 0.00. The current Days Payable is 0.00. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Days Payable is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies IMNN ACXP ENVB CURX LABT PBM NCNA CELZ APM BCLI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

32GF Score

Get the complete analysis for PMCB

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77

Price

View PMCB Analysis

See Days Payable data for all stocks →